1-20 of 128
Cyrille Touzeau
Close
Sort by
Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Clinical Trials & Observations
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Journal: Blood
Blood (2024) 143 (20): 2029–2036.
https://doi.org/10.1182/blood.2023023597
Published: 2024
Includes: Supplemental data
Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Romane Durand, Géraldine Descamps, Céline Bellanger, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Jennifer Derrien, Jonathan Cruard, Stéphane Minvielle, Nicoletta Libera Lilli, Catherine Godon, Yannick Le Bris, Benoit Tessoulin, Martine Amiot, Patricia Gomez-Bougie, Cyrille Touzeau, Philippe Moreau, David Chiron, Agnès Moreau-Aubry, Catherine Pellat-Deceunynck
Journal: Blood
Blood (2024) 143 (13): 1242–1258.
https://doi.org/10.1182/blood.2023021581
Published: 2024
Includes: Supplemental data
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Jesus G. Berdeja, David Dingli, Sagar Lonial, Andrew J. Yee, Alfred Chung, Cristina Gasparetto, P. Leif Bergsagel, Vivek Roy, Al-Ola Abdallah, Sharmilan Thanendrarajan, Aimaz Afrough, Laura Rosiñol, Suzanne Trudel, Paula Rodriguez Otero, Cyrille Touzeau, Pierre Bories, Soo Bang, Terry Connolly, Michelle Kim, Chad A. Lewis, Bao-Van Tran Linberg, M. Travis Quigley, Ola Landgren, Saad Z Usmani, Maria-Victoria Mateos, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3391.
https://doi.org/10.1182/blood-2023-174550
Published: 2023
Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Arthur Bobin, Cyrille Hulin, Jerome Lambert, Aurore Perrot, Salomon Manier, Lydia Montes, Arnaud Jaccard, Lionel Karlin, Pascal Godmer, Denis Caillot, Thomas Chalopin, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Jacques Delaunay, Claire Dingremont, Alberto Santagostino, Mamoun Dib, Margaret Macro, Mourad Tiab, Kamel Laribi, Emmanuelle Bourgeois Petit, Claire Calmettes, Frederique Orsini Piocelle, Benoit Bareau, Reza Tabrizi, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Jill Corre, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6741.
https://doi.org/10.1182/blood-2023-185699
Published: 2023
Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin, Lionel Karlin, Denis Caillot, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoit Bareau, Karim Belhadj Merzoug, Lotfi Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Helene Demarquette, Pierre Feugier, Cécile Sonntag, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Petillon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6724.
https://doi.org/10.1182/blood-2023-186599
Published: 2023
Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Xavier Leleu, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj Merzoug, Adrien Trebouet, Patricia Zunic, Jean Marc Schiano De Colella, Christina Tekle, Marianne Gaucher, Olivier Decaux
Journal: Blood
Blood (2023) 142 (Supplement 1): 7419.
https://doi.org/10.1182/blood-2023-179532
Published: 2023
Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Niels W.C.J. van de Donk, Cyrille Touzeau, Evangelos Terpos, Aurore Perrot, Roberto Mina, Maaike de Ruijter, Elisabetta Antonioli, Eirini Katodritou, Norbert Pescosta, Paulus A.F. Geerts, Cécile Sonntag, Ruth Wester, Angelo Belotti, Silvia Mangiacavalli, Massimo Offidani, Mattia D'Agostino, Mark van Duin, Michele Cavo, Sara Aquino, Alessandra Lombardo, Mark-David Levin, Cyrille Hulin, Mario Boccadoro, Pieter Sonneveld, Francesca Gay
Journal: Blood
Blood (2023) 142 (Supplement 1): 208.
https://doi.org/10.1182/blood-2023-177564
Published: 2023
Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Larysa Sanchez, Carolina Schinke, Amrita Krishnan, Jésus G Berdeja, Niels WCJ van de Donk, María Victoria Mateos, Ajai Chari, Samir Parekh, Tarek H. Mouhieddine, Sundar Jagannath, Nizar J Bahlis, Cyrille Touzeau, Albert Oriol, Jesus San-Miguel, Paula Rodriguez Otero, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Kathleen Gray, Damiette Smit, Christoph Heuck, Leo Rasche
Journal: Blood
Blood (2023) 142 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2023-182330
Published: 2023
Journal Articles

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Jeffrey Matous, Noa Biran, Aurore Perrot, Jésus G Berdeja, Kathleen Dorritie, Janine Van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine Thornton, Damiette Smit, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 1014.
https://doi.org/10.1182/blood-2023-187706
Published: 2023
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Arthur Bobin, Jerome Lambert, Stéfanie Ragot, Aurore Perrot, Salomon Manier, Lionel Karlin, Denis Caillot, Lotfi Benboubker, Thomas Chalopin, Carla Araujo, Jean Fontan, Thorsten Braun, Clara Mariette, Elodie Scherman, Olivier Decaux, jean Sebastien Blade, Faiza Keddar, Christophe Roul, Mamoun Dib, Jill Corre, Frederique Orsini Piocelle, Laure Vincent, Cyrille Touzeau, Philippe Moreau, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6742.
https://doi.org/10.1182/blood-2023-185792
Published: 2023
Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don A. Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Timothy Ming, Eva G Katz, Katharine S Gries, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Philippe Moreau, Jesús San-Miguel, Paula Rodríguez Otero, Ajai Chari
Journal: Blood
Blood (2023) 142 (Supplement 1): 6711.
https://doi.org/10.1182/blood-2023-189151
Published: 2023
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 207.
https://doi.org/10.1182/blood-2023-174044
Published: 2023
Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Sarah Cayla, Benoit Ferment, Noemie Bigot, Denis Caillot, Ingrid Lafon, Lionel Karlin, Anne Lazareth, Cyrille Touzeau, Xavier Leleu, Niels Moya, Stephanie Harel, Aurore Perrot, Pierre Bories, Laure Vincent, Sylvain Lamure, Mohamad Mohty, Florent Malard, Salomon Manier, Ibrahim Yakoub-Agha, Anne-Marie Stoppa, Gabriel Brisou, Olivier Decaux, Roch Houot, Steven Le Gouill, Jerome Lambert, Thierry Facon, Herve Avet Loiseau, Philippe Moreau, Bertrand Arnulf
Journal: Blood
Blood (2023) 142 (Supplement 1): 2139.
https://doi.org/10.1182/blood-2023-188655
Published: 2023
Journal Articles

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Elise Cellerin, Aurelie Jourdes, Xavier Brousse, Nicolas Vallet, Tom Cartau, Blandine Denis, Stephanie Harel, Simon Jamard, Alexis Redor, Titouan Cazaubiel, Virginie Roland, Carine Caleteix, Morgane Charles, Pierre Berger, Guillaume Escure, Aude Collignon, Emmanuel Faure, Clarisse Cazelles, Fanny Lanternier, Clementine de La Porte Des Vaux, Laurent Frenzel, Mathieu Blot, Francois Danion, Cécile Sonntag, Cyrille Touzeau, Andrea Pieragostini, Florence Ader, Lionel Karlin, Margaret Macro, Guillaume martin-Blondel, Thomas Chalopin, Aurore Perrot
Journal: Blood
Blood (2023) 142 (Supplement 1): 1005.
https://doi.org/10.1182/blood-2023-175004
Published: 2023
Journal Articles

Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma

Baptiste Le Calvez, Yannick Le Bris, Thomas Gastinne, Viviane Dubruille, Béatrice Mahé, Nicolas Blin, Anne Lok, Sophie Vantyghem, Clara Sortais, Cyrille Touzeau, Steven Le Gouill, Philippe Moreau, Patrice Chevallier, Marion Eveillard, Marie C Bene, Benoit Tessoulin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12766–12767.
https://doi.org/10.1182/blood-2022-170113
Published: 2022
Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 9995–9997.
https://doi.org/10.1182/blood-2022-163092
Published: 2022
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022
Journal Articles

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Arthur Bobin, Jerome Lambert, Stéphanie Ragot, Aurore Perrot, Salomon Manier, Lionel Karlin, Denis Caillot, Cyrille Hulin, Lotfi Benboubker, Carla Araujo, Jean Fontan, Thorsten Braun, Clara Mariette, Elodie Scherman, Olivier Decaux, jean Sebastien Blade, Faida Keddar, Christophe Roul, Mamoun Dib, Jill Corre, Frederique Orsini, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Philippe Moreau, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4452–4453.
https://doi.org/10.1182/blood-2022-166870
Published: 2022